Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Agenus Inc
AGEN
Healthcare
Biotechnology
Agenus Inc. is a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse...
pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:AGEN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(216)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on May 12, 2025 10:20am
Buy buddy buy.
This stock is signalling a big uptrend for shareholders today and tomorrow and it should keep climbing steadily upward from this point forward
(0)
•••
PressRelease
X
Post by
PressRelease
on Dec 05, 2024 7:31am
New Press Release - Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 27, 2024 8:16am
New Press Release - Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovationhas successfully secured a $22 million non-amortizing mortgage backed by its Berkeley-based Biologics CMC facility ("901 Heinz") and its 66-acre biomanufacturing-zoned property in Vacaville...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 12, 2024 7:06am
New Press Release - Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. “BOT...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 07, 2024 10:04am
New Press Release - Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
Novel Candidates Show Promise in Turning Cold and Refractory Tumors into Responsive Targets Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 4:33pm
New Press Release - November 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - AGEN
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 4:01pm
New Press Release - AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
New York, New York--(Newsfile Corp. - November 5, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ: AGEN) and certain of its officers.Class...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 10:02am
New Press Release - Shareholders that lost money on Agenus Inc. (AGEN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 9:48am
New Press Release - FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 7:32am
New Press Release - Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN
NEW YORK, NY / ACCESSWIRE / November 5, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 7:30am
New Press Release - Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its third quarter 2024 financial results before the market opens on Tuesday, November 12th, 2024. Agenus executives will host a conference...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 7:02am
New Press Release - FINAL AGEN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Agenus Inc. Investors to Join the Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / November 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) and certain of its officers.Class DefinitionThis...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 05, 2024 5:45am
New Press Release - Shareholders that lost money on Agenus Inc.(AGEN) should contact Levi & Korsinsky about pending Class Action - AGEN
NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Agenus investors who were adversely affected by alleged...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 04, 2024 4:21pm
New Press Release - Class Action Filed Against Agenus Inc. (AGEN) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 04, 2024 4:01pm
New Press Release - AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
New York, New York--(Newsfile Corp. - November 4, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ: AGEN) and certain of its officers.Class...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Healthcare and Clinical Stage Drug Development Company Acquires NoBrainer Imaging Centers